OPCR-Lip

**OPCR-Lip** is an investigational chondroitin sulfate-modified liposomal fixed-dose anticancer formulation developed for solid tumors. It incorporates retinoic acid-functionalized liposomes, an MMP-2-responsive PD-L1 inhibitory D-peptide component based on D-PPA-1, and co-encapsulated oxaliplatin. The formulation is designed to target CD44-expressing tumor cells, block membrane PD-L1, disrupt Golgi-dependent PD-L1 glycosylation and exosomal PD-L1 secretion, and induce oxaliplatin-mediated immunogenic cell death. In preclinical 4T1 breast cancer, B16F10 melanoma, and Lewis lung carcinoma models, OPCR-Lip enhanced antitumor immune activity and tumor-growth control.